Cablivi
Cablivi
| Product Specs | Cablivi |
|---|---|
| Manufacturer Name | Sanofi |
| Indications | CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. |
| Contraindications | Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI. |
| Manufacturing Methods | Recombinant DNA technology |
| Viral Safety Process | |
| Route of Administration | Intravenous or subcutaneous use |
| Product Half-Life | The half-life of CABLIVI is concentration and target-level dependent. |
| Shelf Life | 2 months from manufactured date |
| Storage Requirements |
|
| Available Formulations | 11 mg/1 mL |
Return to Manufacturer Name listing Return to Factor Type listing